On 17 September 2025 the General Office of the Shanghai Municipal People's Government issued Hufubangui [2025] No. 8, a five-year (26 September 2025 - 25 September 2030) state-aid framework to accelerate frontier-technology innovation and cultivate "future industries" across six domains — future manufacturing, future information, future materials, future energy, future space and future health. Targeted technology areas include cell and gene therapy, brain-computer interfaces, biomanufacturing, embodied intelligence (humanoid robotics/AI hardware), fourth-generation semiconductors, silicon photonics, 6G, neuromorphic computing, quantum technology, controlled nuclear fusion and regenerative medicine. Support is disbursed as tiered direct subsidies rather than tax relief, with named ceilings up to CNY 30 million per proof-of-concept/R&D platform and CNY 20 million per high-quality incubator or first-product/batch innovation award.

Analyst notesShow

Mechanism

Issued by the Shanghai municipal government's General Office (not a national State Council instrument), this is a sub-national, supply-side state-aid framework aimed squarely at the pre-commercial end of the technology pipeline — proof-of-concept platforms, first-product/batch adoption, incubators and core R&D talent — rather than at manufacturing capacity or export competitiveness (that follow-on layer arrived three months later as Hufubangui [2025] No. 20, the advanced-manufacturing transformation plan: 2025-12-30-shanghai-advanced-manufacturing-transformation-action-plan). Disclosed support ceilings are tiered by instrument:

High-quality incubator construction/operation: up to CNY 20m.
Proof-of-concept and R&D platforms: up to CNY 30m — the largest

single ceiling in the notice, aimed at bridging lab-to-market gaps in the six named future-industry domains.

Basic research investment (one-off supplement): up to CNY 10m.
Small-enterprise growth incentives: up to CNY 500,000.
First-product/first-batch innovation adoption support: up to

CNY 20m — a demand-side de-risking instrument for early buyers of domestically developed frontier products.

Demonstration application-scenario development: up to CNY 8m.
International standard-setting/IP projects: up to CNY 2m.
Core R&D personnel awards: up to CNY 500,000 per individual.

The six target domains (future manufacturing, information, materials, energy, space, health) map onto a broad basket of frontier technologies: cell and gene therapy, brain-computer interfaces, biomanufacturing, embodied intelligence, fourth-generation (wide-bandgap) semiconductors, silicon photonics, 6G, neuromorphic computing, quantum technology, controlled nuclear fusion and regenerative medicine — a materially wider technology basket than the chip-specific finance tracked in china-semiconductor-self-reliance (Big Fund III).

Downstream implications

Pre-commercial layer of Shanghai's industrial-policy stack:

together with Hufubangui [2025] No. 20 (advanced-manufacturing transformation, filed separately), this shows Shanghai running a two-stage municipal subsidy pipeline — early-stage proof-of-concept/incubation funding here, followed by capex-stage manufacturing subsidies three months later — layered on top of national programs (Big Fund III, "Two New").

Embodied intelligence (humanoid robotics) named explicitly:

Shanghai is home to prominent embodied-intelligence startups (e.g. Zhiyuan Robotics/AgiBot); explicit inclusion in a funded state-aid category signals continued municipal capital behind China's humanoid-robotics push, adjacent to but distinct from the December 2025 manufacturing-plan's robot-density targets.

Quantum, fusion and 6G inclusion: places Shanghai alongside

Hefei/Anhui (traditional quantum-tech hub) and national MIIT 6G roadmaps as a funded municipal contributor to frontier-physics and next-gen-telecom bets, relevant when assessing the depth/breadth of China's aggregate state support in FSR/Section 301 overcapacity arguments.

Open questions

Actual disbursement vs. announced ceilings: figures in the

frontmatter are notice-stated caps, not confirmed budget execution; Shanghai Finance Bureau or Statistical Yearbook data would show real uptake.

Overlap with No. 20 and national schemes: whether firms can stack

this proof-of-concept-stage funding with the later manufacturing-stage subsidy (No. 20) and/or national Big Fund III support, raising effective subsidy intensity beyond what any single program discloses.